Blood Reviews
Volume 23, Issue 1 , Pages 1-9 , January 2009

Warfarin and intracranial haemorrhage

  • Rebecca Appelboam

      Affiliations

    • Anaesthesia and Intensive Care Medicine, Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon EX2 5DW, UK
    • Tel.: +44 1392 402474.
    • ,
  • Elfyn O. Thomas

      Affiliations

    • Department of Intensive Care Medicine, Derriford Hospital, Plymouth, Devon PL6 8DH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1752 792555; fax: +44 1752 792548.

References 

  1. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635–641
  2. Levine MN, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:287–310
  3. Franke CL, de Jonge J, van Swieten JC, et al. Intracerebral haematomas during anticoagulant treatment. Stroke. 1990;21:726–730
  4. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–888
  5. Sjöblom L, Hårdemark HG, Lindgreen A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32:2567–2574
  6. Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003;89:278–283
  7. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700–705
  8. Zubhov A, Claassen DO, Rabinstein AA. Warfarin associated intraventricular hemorrhage. Neurol Res. 2007;29:661–663
  9. Rådberg JA, Olsson JE, Rådberg CT. prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571–576
  10. Flibotte JJ, Hagan BA, O’Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–1064
  11. Davis SM, Broderick J, Hennerici M, et al. for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–1181
  12. Hemphill JC, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32:891–897
  13. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
  14. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant associated intracerebral hemorrhage. Neurology. 2007;68(2):116–121
  15. Berwaerts J, Dijkhuizen RS, Robb OJ, et al. Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. Stroke. 2000;31:2558–2562
  16. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333(1):11–17
  17. Acar J, Iung B, Boissel , et al. AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996;94(9):2107–2112
  18. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):401S–428S
  19. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):429S–456S
  20. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):457S–482S
  21. The British Thoracic Society Standards of Care Committee, Pulmonary Embolism Guideline Development Group. BTS Guidelines for the Management of Suspected Acute Pulmonary Embolism. Thorax 2003;48:470–84.
  22. Mayer SA, Lignelli A, Fink ME, et al. Perilesional blood flow and edema formation in acute intracerebral hemorrhage: a SPECT study. Stroke. 1998;29:1791–1798
  23. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Stroke. 2006;37:1465–1470
  24. Wagner KR, Xi G, Hua Y, et al. Lobar intracerebral hemorrhage model in pigs: rapid edema development in perihematomal white matter. Stroke. 1996;27:490–497
  25. Xi G, Wagner KR, Keep RF, et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke. 1998;29:2580–2586
  26. Butler AC, Tait RC. Management of oral anticoagulant – induced intracranial haemorrhage. Blood Rev. 1998;12:35–44
  27. Butchart EG, Gohlke-Bärwolf C, Antunes MJ, et al. on behalf of European Society of Cardiology Recommendations for the management of patients after heart valve surgery. Eur Heart J. 2005;26:2463–2471
  28. Appelboam R, Thomas EO. The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice. Intensive Care Med. 2007;33:1946–1953
  29. Wijdicks EF, Schievink WI, Brown RD, Mullany CJ. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery. 1998;42(4):769–773
  30. Punthakee , Doobay J, Anand SS. Oral-anticoagulant-related intracerebral hemorrhage. Thromb Res. 2003;108:31–36
  31. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol. 2000;57:1710–1713
  32. Butler AC, Tait RC. Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow up. Br J Haematol. 1998;103:1064–1066
  33. Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K. Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol. 1995;44:438–443
  34. Ananthasubramaniam K, Beattie J Rosman H, Jamam V, Borzak S. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage?. Chest. 2001;119:478–484
  35. Shah N, Dawson SL. Intracerebral haemorrhage, prosthetic heart valve and anticoagulation. J RSoc Med. 2004;97:129–130
  36. Crawley F, Bevan D, Wren D. Management of intracranial bleeding associated with anticoagulation: balancing the risk of further bleeding against thromboembolism from prosthetic heart valves. J Neurol Neurosurg Psychiatry. 2000;69:396–398
  37. Babikian VL, Kase CS, Pessin MS, et al. Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves. Stroke. 1988;19:407–408
  38. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82:82–92
  39. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37:256–262
  40. Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin Complex Concentrates: indications, contra-indications, and risks: a task force summary. Thromb Res. 1999;95:S3–S6
  41. Makris M, Watson HG. The management of coumarin-induced over anticoagulation. Br J Haematol. 2001;114:271–280
  42. Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115(1):145–149
  43. The European stroke initiative writing Committee and the Writing Committee for the EUSI Executive Committee. Recommendations for the management of intracranial haemorrhage. Part 1. Spontaneous Intracerebral haemorrhage. Cerebrovasc Dis 2006;22:294–316.
  44. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37:151–155
  45. Lessinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrate in reversing warfarin anticoagulation: a review of the literature. Am J Haematol. 2008;83(2):137–143
  46. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77(3):477–480
  47. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116(3):619–624
  48. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4(5):967–970
  49. Yasaka M, Sakata T, Naritomi H, et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115(6):455–459
  50. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007;121:9–16
  51. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–631
  52. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313–320
  53. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;23:972–977
  54. Yasaka M, Sakata T, Minematsu K, Naritoma H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002;108:25–30
  55. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912–918
  56. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double blind clinical trials. J Trauma. 2005;59:8–18
  57. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879
  58. Ghorashian S, Hunt BJ. “Off-license” use of recombinant activated factor VII. Blood Rev. 2004;18:245–259
  59. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci. 1998;19:163–176
  60. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anti-coagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884–888
  61. Dickneite G. Prothrombin complex Concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Throm Res. 2007;119:643–651
  62. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Throm Res. 2007;
  63. Mayer SA, Brun NC, Begtrup K, et al. for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Recombinant Activated Factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–785
  64. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant factor VII for actute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–2137
  65. Conti S, La Torre D, Gambelunghe G, et al. Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. Clin Lab Haem. 2005;27:283–285
  66. Sørensen B, Johansen P, Nielsen G, et al. Reversal of the International Normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinol. 2003;14:469–477
  67. Freeman WD, Brott TG, Barrett KN, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Procl. 2004;79:1495–1500
  68. Stein DM, Dutton RP, Kramer ME, Handley C, Scalea TM. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma. 2008;64:620–628
  69. (No authors identified) Guidelines on oral anticoagulation. 3rd ed. Br J Haematol 1998;101:374–87.
  70. Baglin TP, Keeling DM, Watson HG for the British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update. Br J Haematol. 2006;132(3):277–285
  71. Hanley JP. Warfarin reversal. J Clin Pathol. 2004;54:1132–1139
  72. Baker RI, Couglin PB, Gallus AS, et al. Warfarin Reversal: consensus guidelines, on behalf of the Australasian Society of thrombosis and haemostasis. Med J Aust. 2004;181:492–497
  73. Ansell J, Hirsch J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119:22S–38S
  74. Mendelow AD, Gregson BA, Fernandes HM, et al. STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the InternationSurgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial. Lancet. 2005;365:387–397
  75. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med. 2001;29(3):635–640
  76. Leker RR, Abramsky O. Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology. 1998;50:1489–1491
  77. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults. Stroke. 2007;38:2001–2003
  78. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710–1716
  79. Bertram M, Bonsato M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol. 2000;247:209–214

PII: S0268-960X(08)00040-4

doi: 10.1016/j.blre.2008.05.001

Blood Reviews
Volume 23, Issue 1 , Pages 1-9 , January 2009

Article Tools